Cargando…
Site-Specific (111)In-Radiolabeling of Dual-PEGylated Porous Silicon Nanoparticles and Their In Vivo Evaluation in Murine 4T1 Breast Cancer Model
Polyethylene glycol (PEG) has been successfully used for improving circulation time of several nanomaterials but prolonging the circulation of porous silicon nanoparticles (PSi NPs) has remained challenging. Here, we report a site specific radiolabeling of dual-PEGylated thermally oxidized porous si...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969933/ https://www.ncbi.nlm.nih.gov/pubmed/31861119 http://dx.doi.org/10.3390/pharmaceutics11120686 |
_version_ | 1783489413989269504 |
---|---|
author | Lumen, Dave Näkki, Simo Imlimthan, Surachet Lambidis, Elisavet Sarparanta, Mirkka Xu, Wujun Lehto, Vesa-Pekka Airaksinen, Anu J. |
author_facet | Lumen, Dave Näkki, Simo Imlimthan, Surachet Lambidis, Elisavet Sarparanta, Mirkka Xu, Wujun Lehto, Vesa-Pekka Airaksinen, Anu J. |
author_sort | Lumen, Dave |
collection | PubMed |
description | Polyethylene glycol (PEG) has been successfully used for improving circulation time of several nanomaterials but prolonging the circulation of porous silicon nanoparticles (PSi NPs) has remained challenging. Here, we report a site specific radiolabeling of dual-PEGylated thermally oxidized porous silicon (DPEG-TOPSi) NPs and investigation of influence of the PEGylation on blood circulation time of TOPSi NPs. Trans-cyclooctene conjugated DPEG-TOPSi NPs were radiolabeled through a click reaction with [(111)In]In-DOTA-PEG(4)-tetrazine (DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and the particle behavior was evaluated in vivo in Balb/c mice bearing 4T1 murine breast cancer allografts. The dual-PEGylation significantly prolonged circulation of [(111)In]In-DPEG-TOPSi particles when compared to non-PEGylated control particles, yielding 10.8 ± 1.7% of the injected activity/g in blood at 15 min for [(111)In]In-DPEG-TOPSi NPs. The improved circulation time will be beneficial for the accumulation of targeted DPEG-TOPSi to tumors. |
format | Online Article Text |
id | pubmed-6969933 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69699332020-02-04 Site-Specific (111)In-Radiolabeling of Dual-PEGylated Porous Silicon Nanoparticles and Their In Vivo Evaluation in Murine 4T1 Breast Cancer Model Lumen, Dave Näkki, Simo Imlimthan, Surachet Lambidis, Elisavet Sarparanta, Mirkka Xu, Wujun Lehto, Vesa-Pekka Airaksinen, Anu J. Pharmaceutics Article Polyethylene glycol (PEG) has been successfully used for improving circulation time of several nanomaterials but prolonging the circulation of porous silicon nanoparticles (PSi NPs) has remained challenging. Here, we report a site specific radiolabeling of dual-PEGylated thermally oxidized porous silicon (DPEG-TOPSi) NPs and investigation of influence of the PEGylation on blood circulation time of TOPSi NPs. Trans-cyclooctene conjugated DPEG-TOPSi NPs were radiolabeled through a click reaction with [(111)In]In-DOTA-PEG(4)-tetrazine (DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and the particle behavior was evaluated in vivo in Balb/c mice bearing 4T1 murine breast cancer allografts. The dual-PEGylation significantly prolonged circulation of [(111)In]In-DPEG-TOPSi particles when compared to non-PEGylated control particles, yielding 10.8 ± 1.7% of the injected activity/g in blood at 15 min for [(111)In]In-DPEG-TOPSi NPs. The improved circulation time will be beneficial for the accumulation of targeted DPEG-TOPSi to tumors. MDPI 2019-12-17 /pmc/articles/PMC6969933/ /pubmed/31861119 http://dx.doi.org/10.3390/pharmaceutics11120686 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lumen, Dave Näkki, Simo Imlimthan, Surachet Lambidis, Elisavet Sarparanta, Mirkka Xu, Wujun Lehto, Vesa-Pekka Airaksinen, Anu J. Site-Specific (111)In-Radiolabeling of Dual-PEGylated Porous Silicon Nanoparticles and Their In Vivo Evaluation in Murine 4T1 Breast Cancer Model |
title | Site-Specific (111)In-Radiolabeling of Dual-PEGylated Porous Silicon Nanoparticles and Their In Vivo Evaluation in Murine 4T1 Breast Cancer Model |
title_full | Site-Specific (111)In-Radiolabeling of Dual-PEGylated Porous Silicon Nanoparticles and Their In Vivo Evaluation in Murine 4T1 Breast Cancer Model |
title_fullStr | Site-Specific (111)In-Radiolabeling of Dual-PEGylated Porous Silicon Nanoparticles and Their In Vivo Evaluation in Murine 4T1 Breast Cancer Model |
title_full_unstemmed | Site-Specific (111)In-Radiolabeling of Dual-PEGylated Porous Silicon Nanoparticles and Their In Vivo Evaluation in Murine 4T1 Breast Cancer Model |
title_short | Site-Specific (111)In-Radiolabeling of Dual-PEGylated Porous Silicon Nanoparticles and Their In Vivo Evaluation in Murine 4T1 Breast Cancer Model |
title_sort | site-specific (111)in-radiolabeling of dual-pegylated porous silicon nanoparticles and their in vivo evaluation in murine 4t1 breast cancer model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969933/ https://www.ncbi.nlm.nih.gov/pubmed/31861119 http://dx.doi.org/10.3390/pharmaceutics11120686 |
work_keys_str_mv | AT lumendave sitespecific111inradiolabelingofdualpegylatedporoussiliconnanoparticlesandtheirinvivoevaluationinmurine4t1breastcancermodel AT nakkisimo sitespecific111inradiolabelingofdualpegylatedporoussiliconnanoparticlesandtheirinvivoevaluationinmurine4t1breastcancermodel AT imlimthansurachet sitespecific111inradiolabelingofdualpegylatedporoussiliconnanoparticlesandtheirinvivoevaluationinmurine4t1breastcancermodel AT lambidiselisavet sitespecific111inradiolabelingofdualpegylatedporoussiliconnanoparticlesandtheirinvivoevaluationinmurine4t1breastcancermodel AT sarparantamirkka sitespecific111inradiolabelingofdualpegylatedporoussiliconnanoparticlesandtheirinvivoevaluationinmurine4t1breastcancermodel AT xuwujun sitespecific111inradiolabelingofdualpegylatedporoussiliconnanoparticlesandtheirinvivoevaluationinmurine4t1breastcancermodel AT lehtovesapekka sitespecific111inradiolabelingofdualpegylatedporoussiliconnanoparticlesandtheirinvivoevaluationinmurine4t1breastcancermodel AT airaksinenanuj sitespecific111inradiolabelingofdualpegylatedporoussiliconnanoparticlesandtheirinvivoevaluationinmurine4t1breastcancermodel |